Clinimix (amino acids in dextrose) Injections

Now Available Clinimix [amino acids in dextrose] and Clinimix E [amino acids with electrolytes in dextrose and calcium] Injections with higher protein* -- the first and only premix formulations with up to 80 grams of amino acids per liter.1,2,3 Higher protein Clinimix formulations are available in 8/14 and 8/10, with and without electrolytes, and in 6/5, which is formulated for peripheral delivery. *Protein is provided as amino acids.

 

Indications

Clinimix sulfite-free (amino acid in dextrose) Injections and Clinimix E sulfite-free (amino acid with electrolytes in dextrose and calcium) Injections are indicated as a source of calories and protein (and electrolytes for Clinimix E) for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Clinimix and Clinimix E may be used to treat negative nitrogen balance in patients. Please read the accompanying full Indication(s) and Important Risk Information, as well as the Package Insert for full Prescribing Information for Clinimix and Clinimix E.

Most Critically Ill Patients Receive Half the Recommended Protein During Their First Week in the ICU4

A nurse hangs a bag of Clinimix E for a patient who is receiving parenteral nutrition (PN)

Critically ill adult patients may lose nearly 1 KG a day of muscle mass, particularly in the first 5 days of ICU stay.5

Protein, not calories, is the crucial macronutrient in catabolic critical illness.4

Clinimix is a ready-to-use amino acids in dextrose parenteral nutrition (PN) solution NOW AVAILABLE with higher protein (amino acid) and with and without electrolytes.

Clinimix is appropriate for adult and pediatric use and is available in a variety of formulations in one-liter and two-liter bags, offering clinicians flexibility to help meet the nutritional goals of each patient.

Please read the accompanying full Indication(s) and Important Risk Information, as well as the Package Insert for full Prescribing Information for Clinimix and Clinimix E.

Clinimix With HIGHER PROTEIN [amino acids] Helps Deliver Nutrition Care as Unique as Each Patient

Reach protein targets in less fluid with Clinimix High Protein.

REACH PROTEIN TARGETS IN LESS FLUID

With up to 80 g/L of protein, higher protein Clinimix formulations enable you to reach guideline recommended doses for protein in less fluid than any other ready-to-use option.1,2*

 

*When comparing formulations 8/10 and 8/14 to formulations 5/15 and 5/20

Reduce calories from dextrose with Clinimix High Protein.

REDUCE CALORIES FROM DEXTROSE

Protein, not calories, is the crucial macronutrient in catabolic critical Illness.4 Higher protein Clinimix formulations offer the most protein per liter and deliver more calories from protein than from dextrose. 1-3**

 

**When compared to other multi-chamber bags available in the U.S.

Choose From Formulations As Distinct As Your Patients With Clinimix High Protein.

CHOOSE FROM FORMULATIONS AS DISTINCT AS YOUR PATIENTS

With higher protein Clinimix, the Clinimix series of ready-to-use formulas offers 14 distinct formulations, available in different volumes, with and without electrolytes. 1,2

A healthcare professional selects a protein molecule to represent choosing Clinimix Injections with Higher Protein.

Clinimix and Clinimix E Now Available with Higher Protein

  • Source of calories and protein/amino acid [and electrolytes with Clinimix E]
  • Only premix products formulated with up to 80 grams of amino acids per liter to meet SCCM/ASPEN guidelines for protein intake in critically ill patients6
  • Suitability for the majority of PN patients
  • 24-month shelf life
  • Vertical Peel Seal CLARITY Dual Chamber container in 1L and 2L sizes
  • Flexibility with seven formulations of Clinimix E and seven formulations of Clinimix

Please read the accompanying full Indication(s) and Important Risk Information, as well as the Package Insert for full Prescribing Information for Clinimix and Clinimix E.

Choose From Formulations As Distinct As Your Patients

Clinimix Composition Graphic

Clinimix 8/14 ready-to-use formula

8% Amino Acid

14% Dextrose

 

Composition (based on the maximum available in other Clinimix variants):

Protein/Amino Acid: 80 g/L

Dextrose: 140 g/L

Total kcal: 797 kcal/L

 

Available with and without electrolytes

Clinimix 8/10 ready-to-use formula

8% Amino Acid

10% Dextrose

 

Composition (based on the maximum available in other Clinimix variants):

Protein/Amino Acid: 80 g/L

Dextrose: 100 g/L

Total kcal: 663 kcal/L

 

Available with and without electrolytes

Clinimix 6/5 ready-to-use formula

6% Amino Acid

5% Dextrose

 

Composition (based on the maximum available in other Clinimix variants):

Protein/Amino Acid: 60 g/L

Dextrose: 50 g/L

Total kcal: 410 kcal/L

 

Formulated for peripheral delivery

Selected Important Risk Information

● As with all injectable products, there are risks associated with Clinimix and Clinimix E, including being contraindicated in patients with known hypersensitivity to one or more amino acids or dextrose; in patients with inborn errors of amino acid metabolism due to risk of severe metabolic and neurologic complications; arid in patients with pulmonary edema or acidosis due to low cardiac output.

● In addition, Clinimix E is contraindicated in neonates (less than 28 days of age) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone calcium salt precipitation in the neonate's bloodstream.

2-Port Clinimix / Clinimix E Bag Activation – Instructional Poster 

3-Port Clinimix / Clinimix E Bag Activation  – Video Below

Please read the accompanying full Indication(s) and Important Risk Information and the Package Insert for full Prescribing Information for Clinimix and Clinimix E.

Request a TPN Order Analysis

This form is intended for a U.S. healthcare professional.
To receive electronic marketing communications about Baxter’s products and services, please review the Baxter Privacy Notices, complete the form below and give your consent by ticking the box. Privacy Notices, complete the form below and give your consent by ticking the box.

TPN Order Analysis

Explore Our Related Products

Pharmacist works at ExactaMix in hospital pharmacy

ExactaMix Compounder

Product photo of Amico Acids

Amino Acid Injections

Product photo of Infuvite -- Vitamins for Infusion

Infuvite— Multivitamins for Infusion

Product image of Clinolipid

Clinolipid 20% Lipid Injectable Emulsion, USP

Please click here for Full Prescribing information.

Product photo of Q-NRG+ monitor

Q-NRG+ Metabolic Monitor

Indications and Important Risk Information for CLINIMIX

Indications

CLINIMIX (amino acids in dextrose) Injections and CLINIMIX E (amino acids with electrolytes in dextrose with calcium) Injections are indicated as a source of calories and protein (and electrolytes for CLINIMIX E) for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX and CLINIMIX E may be used to treat negative nitrogen balance in patients.

Important Risk Information

  • CLINIMIX and CLINIMIX E Injections are contraindicated in patients with known hypersensitivity to one or more amino acids or dextrose; in patients with inborn errors of amino acid metabolism due to risk of severe metabolic and neurologic complications; and in patients with pulmonary edema or acidosis due to low cardiac output. In addition, CLINIMIX E is contraindicated in neonates (less than 28 days of age) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone calcium salt precipitation in the neonate’s bloodstream.
  • Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. Excess addition of calcium and phopshate increases the risk of the formation of calcium phosphate precipitates. The solution should be inspected for precipitates before admixing, after admixing, and again before administration. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation.
  • Precipitation of ceftriaxone-calcium can occur when ceftriaxone is mixed with CLINIMIX E, in the same intravenous administration line. Do not administer ceftriaxone simultaneously with CLINIMIX E via a Y-site.
  • Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity reaction develop.
  • Monitor for signs and symptoms of early infections.
  • Refeeding severely undernourished patients may result in refeeding syndrome. Thiamine deficiency and fluid retention may also develop. Monitor severely undernourished patients and slowly increase nutrient intakes.
  • CLINIMIX and CLINIMIX E solutions containing more than 5% dextrose have an osmolarity of ≥ 900 mOsm/L and must be infused through a central catheter.
  • CLINIMIX and CLINIMIX E contain no more than 25 mcg/L of aluminum which may reach toxic levels with prolonged administration in patients with renal impairment. Preterm infants are at greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions which contain aluminum. Patients with renal impairment, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
  • Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants. If CLINIMIX and CLINIMIX E treated patients develop liver test abnormalities consider discontinuation or dosage reduction.
  • Use CLINIMIX and CLINIMIX E with caution in patients with cardiac insufficiency or renal impairment due to increased risk of electrolyte and fluid volume imbalance.
  • Monitor renal and liver function parameters, ammonia levels, fluid and electrolyte status, serum osmolarity, blood glucose, blood count and coagulation parameters throughout treatment. In situations of severely elevated electrolyte levels, stop CLINIMIX and CLINIMIX E until levels have been corrected.
  • Adverse reactions include diuresis, extravasation, glycosuria, hyperglycemia, and hyperosmolar coma.

Please click here for full Prescribing Information for Clinimix.
Please click here for full Prescribing Information for Clinimix E.